Dr. Manuel Alós Almiñana

Principal Investigator
Associated Clinical Group in Pharmacy

Presentation

Dr. Manuel Alós Almiñana
Principal
Investigator
Dr. Manuel Alós Almiñana

alos_man@gva.es, manuel.alos@uv.es

Publications
Health outcomes and primary adherence to secondary prevention treatment after st-elevation myocardial infarction: a spanish cohort study. Lopez A, Alos Almiñana M, Peris J. Journal of Cardiovascular Translational Research. 2021 Apr;14(2):308-316. doi: 10.1007/s12265-020-10045-0. PMID: 32557320

MUC1 intracellular bioactivation mediates lung fibrosis. Milara Paya J, Ballester B, Montero P, Escriva J, Artigues E, Alos Almiñana M, Pastor–Clerigues A, Morcillo Sánchez E, Cortijo J. Thorax. 2020 Feb;75(2):132-142. doi: 10.1136/thoraxjnl-2018-212735. PMID: 31801904

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances. Aguilar Aguilar G, Ferriols Lisart R, Martínez Castro S, Ezquer Garin C, Pastor Martinez E, Carbonell Lopez J, Alos Almiñana M, Navarro Ortega D. Critical Care. 2020 Jan 10;24(1):11. doi: 10.1186/s13054-019-2724-y. PMID: 31924240

Secondary adherence to beta-blockers after ST-elevation myocardial infarction without ventricular dysfunction. Padilla Lopez A, Alos Almiñana M, Peris J. Medicina Clinica. 2020 Sep 25;155(6):242-248. doi: 10.1016/j.medcli.2019.11.008. PMID: 31932044

Stability of tedizolid phosphate-sodium rifampicin and tedizolid phosphate-meropenem admixtures in intravenous infusion bags stored at different temperatures. Ezquer Garin C, Ferriols Lisart R, Martinez-López L, Sangrador-Pelluz C, Nicolás-Picó J, Alos Almiñana M. Pharmazie. 2020 May 1;75(5):172-176. doi: 10.1691/ph.2020.9155. PMID: 32393422